PharmaTimesNews & Politicsnews

Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen

Tuesday, May 26, 2026John PinchingView original

Data shows survival benefit in BRAFV600E‑mutant metastatic colorectal cancer

Read the full article on the original site.

Read Full Article